227 related articles for article (PubMed ID: 11794886)
81. Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia.
Tharoor H; Goyal A
Arch Womens Ment Health; 2015 Oct; 18(5):741-2. PubMed ID: 26189131
[TBL] [Abstract][Full Text] [Related]
82. Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.
Reid IR
Expert Opin Drug Saf; 2002 May; 1(1):93-107. PubMed ID: 12904164
[TBL] [Abstract][Full Text] [Related]
83. Raloxifene: bone and cardiovascular effects.
Francucci CM; Romagni P; Boscaro M
J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
[TBL] [Abstract][Full Text] [Related]
84. [Therapy of postmenopausal osteoporosis].
Keck E
Orthopade; 2003 Dec; 32(12):1104-9. PubMed ID: 14655007
[TBL] [Abstract][Full Text] [Related]
85. [Hormone therapy and breast cancer: a review].
Lucchi-Angellier E
Rev Med Interne; 2001 Dec; 22(12):1213-24. PubMed ID: 11794892
[TBL] [Abstract][Full Text] [Related]
86. [Raloxifene for the treatment of osteoporosis].
Okazaki R
Nihon Naika Gakkai Zasshi; 2005 Apr; 94(4):702-7. PubMed ID: 15864998
[No Abstract] [Full Text] [Related]
87. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial.
Wenger NK; Barrett-Connor E; Collins P; Grady D; Kornitzer M; Mosca L; Sashegyi A; Baygani SK; Anderson PW; Moscarelli E
Am J Cardiol; 2002 Dec; 90(11):1204-10. PubMed ID: 12450599
[TBL] [Abstract][Full Text] [Related]
88. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].
Simoncini T; Mannella P; Genazzani AR
Recenti Prog Med; 2003 Feb; 94(2):51-6. PubMed ID: 12908369
[TBL] [Abstract][Full Text] [Related]
89. NCI and the STELLAR trial.
The Lancet
Lancet; 2007 Jun; 369(9580):2134. PubMed ID: 17604779
[No Abstract] [Full Text] [Related]
90. [Raloxifene, selective estrogen receptor modulator (SERM). Introduction and conclusion].
Audran M
Joint Bone Spine; 2000; 67 Suppl 1():3s-6s, 23s-25s. PubMed ID: 10769108
[No Abstract] [Full Text] [Related]
91. Serum estradiol level and risk of breast cancer during treatment with raloxifene.
Cummings SR; Duong T; Kenyon E; Cauley JA; Whitehead M; Krueger KA;
JAMA; 2002 Jan; 287(2):216-20. PubMed ID: 11779264
[TBL] [Abstract][Full Text] [Related]
92. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
93. Recruitment of women into trials.
Benson JR
Lancet; 2002 Jan; 359(9301):164. PubMed ID: 11809281
[No Abstract] [Full Text] [Related]
94. An update on breast cancer prevention trials.
Wickerham DL; Fourchotte V
Int J Gynecol Cancer; 2006; 16 Suppl 2():498-501. PubMed ID: 17010056
[TBL] [Abstract][Full Text] [Related]
95. [Diabetes, Conn syndrome and osteoporosis. What is new in diagnosis and therapy?].
Reincke M
MMW Fortschr Med; 2003 Feb; 145(9):29. PubMed ID: 12769132
[No Abstract] [Full Text] [Related]
96. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
[TBL] [Abstract][Full Text] [Related]
97. Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis.
Melamed ML; Blackwell T; Neugarten J; Arnsten JH; Ensrud KE; Ishani A; Cummings SR; Silbiger SR
Kidney Int; 2011 Jan; 79(2):241-9. PubMed ID: 20927038
[TBL] [Abstract][Full Text] [Related]
98. Medication update.
Slagle MA
South Med J; 2001 Jun; 94(6):574-8. PubMed ID: 11440325
[No Abstract] [Full Text] [Related]
99. [Raloxifene: a selective modulator of estrogen receptors].
van den Brûle FA; Kalbus MF; Gaspard UJ
J Gynecol Obstet Biol Reprod (Paris); 1999 Dec; 28(8):788-99. PubMed ID: 10635481
[TBL] [Abstract][Full Text] [Related]
100. Design and methods of the Raloxifene Use for The Heart (RUTH) study.
Mosca L; Barrett-Connor E; Wenger NK; Collins P; Grady D; Kornitzer M; Moscarelli E; Paul S; Wright TJ; Helterbrand JD; Anderson PW
Am J Cardiol; 2001 Aug; 88(4):392-5. PubMed ID: 11545760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
